You are here: Industry Insights > Breast Cancer

News List

Everest Medicines Initiates Submission of New Drug Application in Singapore for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer prnasia
January 07, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced that it has ...
FDA grants ARX788 fast track designation for HER2-positive metastatic breast cancer pharmaceutical-business-review
January 07, 2021
Ambrx announced that the US Food and Drug Administration (FDA) granted ARX788 Fast Track Designation as monotherapy for the treatment of advanced or metastatic HER2-positive breast cancer patients who have received one or more prior anti-HER2 based ...
Roche gets EC nod for Phesgo to treat HER2-positive breast cancer pharmaceutical-business-review
December 30, 2020
Roche has secured approval from the European Commission (EC) for its Phesgo to treat early and metastatic HER2-positive breast cancer.
First Patient Dosed in Phase 3 Registration Asian Study of Trodelvy for Breast Cancer americanpharmaceuticalreview
December 30, 2020
Everest Medicines announced the first patient has been dosed in the Phase 3 registration Asian study EVER-132-002 evaluating TrodelvyTM (sacituzumab govitecan) versus treatment of physician’s choice (TPC) in subjects with hormonal ...
Novartis’ Kisqali demonstrates nearly five years median OS in metastatic breast cancer pharmaceutical-business-review
December 14, 2020
Novartis announced updated median overall survival (OS) results for Kisqali (ribociclib) in combination with endocrine therapy, marking the longest survival data ever reported in premenopausal women with hormone receptor positive, human epidermal ...
Enhertu scores ‘impressive’ new data in HER2 breast cancer pharmatimes
December 11, 2020
AstraZeneca (AZ) and Daiichi Sankyo have reported updated results from a phase II trial of Enhertu, which continued to demonstrate ‘impressive’ efficacy in patients with HER2-positive metastatic breast cancer.
New potential breast cancer drugs identified expresspharma
November 27, 2020
The potential drug offers hope for patients whose breast cancer has become resistant to traditional therapies.
FDA approves Merck’s Keytruda with chemotherapy to treat breast cancer pharmaceutical-technology
November 17, 2020
Merck (MSD) has secured approval from the US Food and Drug Administration (FDA) for its Keytruda in combination with chemotherapy for treating patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumours ..
New Research Study Supports Clinical Utility of Circulating Tumor Cell Count for Metastatic Breast Cancer prnasia
November 09, 2020
Menarini Silicon Biosystems, the pioneer of liquid biopsy technology, today announced the publication of a research study providing support for the reliability of using circulating tumor cell (CTC) count to guide frontline therapy choice for patients ...
NBE-Therapeutics Begins Anti-ROR1 ADC Study for Solid Tumors americanpharmaceuticalreview
October 30, 2020
NBE-Therapeutics has commenced first-in-human studies of its lead program NBE-002 targeting ROR1, for triple negative breast cancer (TNBC) and other solid tumors.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 26 27 Next page